Another notable finding is the effect of 100 mg of aspirin daily on mucosal bleeding in F5D patients. P2Y12 generally plays a key role in dual antiplatelet therapy (DAPT). In this instance, the AUC values of aspirin and ticagrelor were 8 and 10, with 100 mg of aspirin daily and 90 mg of ticagrelor twice a day, respectively. The AUC value for ticagrelor was 22 for a daily regimen of 100 mg of aspirin and 90 mg of ticagrelor, but the AUC for ticagrelor increased to 52 when only the 90 mg of ticagrelor was maintained. This observation emphasizes that ticagrelor's antithrombotic effect is affected by aspirin. In fact, the Platelet Inhibition and Patient Outcomes trial showed that daily combination of 100 mg of aspirin and ticagrelor was superior to aspirin and clopidogrel combined, but the use of 300 mg/day of aspirin wiped out the benefit. Moreover, Kirkby et al demonstrated that aspirin provides additional antiaggregatory effects when only a partial P2Y12 blockade is achieved. Daily 90 mg of ticagrelor administration means incomplete P2Y12 inhibition and 100 mg of aspirin has the enhancing effect of suppressing platelet aggregation for the daily dose of 90 mg of ticagrelor. Aspirin discontinuance with a daily dose of 90 mg of ticagrelor causes ticagrelor to have a weakened antiplatelet effect, which can be expressed as an increased AUC value for ticagrelor. Meanwhile, it is unclear whether the disappearance of mucosal bleeding after stopping aspirin can be ascribed to the antithrombotic effect of aspirin itself or its excessive dose (100 mg/day). However, as the daily dose of 100 mg of aspirin may have had a strong antithrombotic effect in a patient with F5D and mucosal bleeding; aspirin may have to be stopped to control mucosal bleeding when simultaneously taking a P2Y12 receptor blocker.